| Alternative Name: | Bcl-2-modifying factor |
| |
| Host: | Rabbit |
| |
| Immunogen: | Synthetic peptide corresponding to the sequence near the N-terminus of human Bmf. |
| |
| UniProt ID: | Q96LC9 |
| |
| Species reactivity: | Human, Mouse
|
| |
| Applications: | ICC, WB
|
| |
| Recommended Dilutions/Conditions: | Western Blot (2µg/ml, HepG2 or 293 cell lysates can be used for positive control)
Suggested dilutions/conditions may not be available for all applications.
Optimal conditions must be determined individually for each application. |
| |
| Application Notes: | Detects a band of ~25kDa by Western blot. |
| |
| Purity Detail: | Peptide affinity purified. |
| |
| Formulation: | Liquid. In PBS containing 0.02% sodium azide. |
| |
| Shipping: | Blue Ice |
| |
| Long Term Storage: | -20°C |
| |
| Scientific Background: | Bmf (Bcl-2 modifying factor) is a member of the Bcl-2 family of apoptotic proteins. The BH3 domain in Bmf is required both for binding to Bcl-2 proteins and for triggering apoptosis. In healthy cells, Bmf associates with the Dynein light chain 2 (DLC2), a component of the myosin V motors, and is sequestered by the cell's actin cytoskeleton. Disruption of the actin cytoskeleton triggers release and activation of Bmf, initiating the downstream apoptotic program. |
| |
| Regulatory Status: | RUO - Research Use Only |
| |
